Latest Insider Transactions at Nektar Therapeutics (NKTR)
This section provides a real-time view of insider transactions for Nektar Therapeutics (NKTR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEKTAR THERAPEUTICS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEKTAR THERAPEUTICS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 20
2021
|
Robert Chess |
BUY
Exercise of conversion of derivative security
|
Direct |
2,106
+0.74%
|
$27,378
$13.8 P/Share
|
|
May 17
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
7,898
-3.05%
|
$142,164
$18.3 P/Share
|
|
May 17
2021
|
John Northcott SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,085
-2.85%
|
$109,530
$18.3 P/Share
|
|
May 17
2021
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
11,560
-2.59%
|
$208,080
$18.3 P/Share
|
|
May 17
2021
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,391
-8.14%
|
$241,038
$18.3 P/Share
|
|
May 17
2021
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,917
-2.5%
|
$34,506
$18.3 P/Share
|
|
May 17
2021
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
31,111
-11.69%
|
$559,998
$18.3 P/Share
|
|
May 12
2021
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
8,000
-2.77%
|
$152,000
$19.34 P/Share
|
|
May 12
2021
|
Robert Chess |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+2.7%
|
$104,000
$13.8 P/Share
|
|
Apr 14
2021
|
Robert Chess |
SELL
Open market or private sale
|
Direct |
8,000
-2.77%
|
$144,000
$18.98 P/Share
|
|
Apr 14
2021
|
Robert Chess |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+2.7%
|
$104,000
$13.8 P/Share
|
|
Feb 16
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
7,977
-2.99%
|
$175,494
$22.37 P/Share
|
|
Feb 16
2021
|
John Northcott SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,358
-6.72%
|
$337,876
$22.37 P/Share
|
|
Feb 16
2021
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
11,495
-2.51%
|
$252,890
$22.37 P/Share
|
|
Feb 16
2021
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,705
-6.64%
|
$257,510
$22.37 P/Share
|
|
Feb 16
2021
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,173
-2.75%
|
$47,806
$22.37 P/Share
|
|
Feb 16
2021
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
24,141
-8.32%
|
$531,102
$22.37 P/Share
|
|
Feb 04
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
50,000
-15.77%
|
$950,000
$19.81 P/Share
|
|
Feb 04
2021
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+13.63%
|
$400,000
$8.8 P/Share
|
|
Feb 04
2021
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
150,000
-13.17%
|
$3,000,000
$20.34 P/Share
|
|
Feb 04
2021
|
Howard W Robin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+19.77%
|
$1,200,000
$8.8 P/Share
|
|
Feb 03
2021
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,344
-6.34%
|
$101,536
$19.45 P/Share
|
|
Feb 03
2021
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Exercise of conversion of derivative security
|
Direct |
5,344
-5.97%
|
$42,752
$8.8 P/Share
|
|
Feb 03
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
50,000
-15.77%
|
$950,000
$19.61 P/Share
|
|
Feb 03
2021
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.6%
|
$400,000
$8.8 P/Share
|
|
Feb 03
2021
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
150,000
-24.64%
|
$2,850,000
$19.72 P/Share
|
|
Feb 03
2021
|
Howard W Robin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+11.65%
|
$1,200,000
$8.8 P/Share
|
|
Feb 02
2021
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
50,000
-5.4%
|
$1,000,000
$20.86 P/Share
|
|
Feb 02
2021
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+13.63%
|
$400,000
$8.8 P/Share
|
|
Feb 02
2021
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
150,000
-8.39%
|
$3,000,000
$20.71 P/Share
|
|
Feb 02
2021
|
Howard W Robin President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+19.77%
|
$1,200,000
$8.8 P/Share
|
|
Jan 28
2021
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
75,000
-29.85%
|
$1,350,000
$18.62 P/Share
|
|
Jan 28
2021
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+13.96%
|
$600,000
$8.8 P/Share
|
|
Jan 05
2021
|
R Scott Greer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+15.06%
|
$520,000
$13.8 P/Share
|
|
Dec 30
2020
|
Roy A Whitfield |
BUY
Bona fide gift
|
Indirect |
51,500
+50.0%
|
-
|
|
Dec 30
2020
|
Roy A Whitfield |
SELL
Bona fide gift
|
Direct |
51,500
-21.7%
|
-
|
|
Dec 18
2020
|
Gil M Labrucherie SVP, COO & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+13.03%
|
-
|
|
Dec 18
2020
|
John Northcott SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,550
+11.1%
|
-
|
|
Dec 18
2020
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
106,650
+18.86%
|
-
|
|
Dec 18
2020
|
Jillian B. Thomsen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+8.32%
|
-
|
|
Dec 18
2020
|
Mark Andrew Wilson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,550
+26.57%
|
-
|
|
Dec 18
2020
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+12.11%
|
-
|
|
Dec 15
2020
|
Myriam Curet Director |
SELL
Open market or private sale
|
Direct |
1,560
-7.5%
|
$26,520
$17.82 P/Share
|
|
Nov 23
2020
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
16,380
-6.14%
|
$262,080
$16.4 P/Share
|
|
Nov 16
2020
|
Gil M Labrucherie SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
8,276
-3.52%
|
$132,416
$16.93 P/Share
|
|
Nov 16
2020
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
11,975
-3.29%
|
$191,600
$16.93 P/Share
|
|
Nov 16
2020
|
Jillian B. Thomsen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,976
-6.97%
|
$191,616
$16.93 P/Share
|
|
Nov 16
2020
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,539
-2.99%
|
$24,624
$16.93 P/Share
|
|
Nov 16
2020
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
29,618
-10.0%
|
$473,888
$16.93 P/Share
|
|
Sep 28
2020
|
Jeffrey Robert Ajer |
SELL
Open market or private sale
|
Direct |
3,250
-11.12%
|
$55,250
$17.25 P/Share
|